Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss ... Health Organization to endorse the inclusion of rapid-acting insulin analogues and GLP-1 receptor agonists (RAs) on the ...

Novo Nordisk's insulin aspart franchise is a ... having a biosimilar option for their rapid-acting insulin injection can truly make a difference, as biosimilar products have the potential to ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO ... In 2004, Levemir – a long-acting modern insulin – was launched. Under Sorensen, the company develops its first GLP-1 drug ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

As a pioneer in diabetes care, Novo Nordisk has been in the business ... Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from US pricing pressure due ...